A practical guide to the management of HCV infection following liver transplantation

Area of Science:

• Hepatology
• Transplantation Immunology
• Virology

Background:

• Hepatitis C-associated liver failure is a primary indication for liver transplantation.
• Virological recurrence of Hepatitis C Virus (HCV) post-transplant is nearly universal.
• Severe HCV recurrence leads to graft loss or death in up to 30% of recipients within five years.

Purpose of the Study:

• To outline strategies for minimizing severe HCV recurrence after liver transplantation.
• To define optimal timing and dosing for antiviral therapy in HCV-infected liver transplant recipients.

Main Methods:

• Review of current clinical practices and evidence regarding HCV recurrence post-liver transplant.
• Analysis of strategies to minimize recurrence, including donor selection and immunosuppression management.
• Evaluation of antiviral treatment protocols, specifically peginterferon and ribavirin, for pre- and post-transplant use.

Main Results:

• Minimizing immunosuppression, particularly T-cell depleting therapies and pulsed corticosteroids, can reduce severe HCV recurrence.
• HCV recurrence is a significant cause of long-term morbidity and mortality in liver transplant recipients.
• Peginterferon and ribavirin are recommended treatments, with dosing adjusted for renal function due to hemotoxicity and renal insufficiency.

Conclusions:

• Proactive management of immunosuppression and timely antiviral treatment are crucial for improving outcomes in liver transplant recipients with HCV.
• Treatment with peginterferon and ribavirin should be considered before liver transplant (LT) for patients with MELD ≤ 17 or upon histological evidence of recurrence post-LT.
• Careful dosing of ribavirin based on renal function is essential to mitigate adverse effects like hemotoxicity and renal insufficiency.